Syndax Pharmaceuticals (SNDX) Receivables (2023 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Receivables of $62.8 million for Q1 2026, up 141.4% year-over-year from $26.0 million in Q1 2025, and up 41.48% quarter-over-quarter from $44.4 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Receivables (2023 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Receivables history runs 4 years deep, the most recent figure standing at $62.8 million for Q1 2026.
- In Q1 2026, Receivables rose 141.4% year-over-year to $62.8 million; the TTM figure through Mar 2026 stood at $62.8 million (up 141.4% YoY), while the FY2025 annual figure was $66.1 million, up 488.2% from the prior year.
- Receivables for Q1 2026 stood at $62.8 million, up from $44.4 million in the prior quarter.
- The five-year high for Receivables was $62.8 million in Q1 2026, with the low at $1.2 million in Q4 2023.
- The 4-year median for Receivables is $36.1 million (2025), against an average of $32.6 million.
- The sharpest annual moves came in 2024 and 2026: Receivables surged 815.81% in 2024, then soared 141.4% in 2026.
- Syndax Pharmaceuticals' Receivables stood at $1.2 million in 2023, then soared by 815.81% to $11.2 million in 2024, then surged by 295.12% to $44.4 million in 2025, then soared by 41.48% to $62.8 million in 2026.
- Business Quant data shows SNDX's Receivables at $62.8 million in Q1 2026, $44.4 million in Q4 2025, and $46.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 71.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.47 Mn |
| Mar 31, 2026 | 62.82 Mn |
| Dec 31, 2025 | 44.40 Mn |
| Sep 30, 2025 | 46.30 Mn |
| Jun 30, 2025 | 36.05 Mn |
| Mar 31, 2025 | 26.02 Mn |
| Dec 31, 2024 | 11.24 Mn |
| Dec 31, 2023 | 1.23 Mn |